Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Latest Information Update: 27 Nov 2024
At a glance
- Drugs Carboplatin (Primary) ; Dostarlimab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Endometrial cancer
- Focus Therapeutic Use
- Acronyms DOMENICA
Most Recent Events
- 18 Jan 2024 Recruitment completion is expected on 1 Aug 2025, according to ISRCTN: Current Controlled Trials.
- 06 Jun 2023 A protocol amendment is submitted to increase patient population (with extended eligibility criteria, PFS hypothesis) according to Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology